证券代码：300981 证券简称：中红医疗 中红普林医疗用品股份有限公司 2024 年度暨 2025 年第一季度网上业绩说明会 投资者关系活动记录表 编号：2025—001 4、中红股票长期低于发行价，低于净资产，连续三年亏损， 口碑不甚好，请问贵公司如何扭转此局面？有哪些行之有效之措 施？谢谢 其次，公司产品矩阵不断完善。公司一次性丁腈手套将持续 保持国内头部位置；安全套系列产品占比在国内市场位居国产品 牌头部，高毛利产品占比有望进一步提升；泵类产品不断迭代更 新，助力开拓市场稳步进行；投资并购持续发力，创新类产品不 断丰富。公司产品矩阵通过内涵发展和外延并购等方式不断完 善，多产品协同优势将逐步凸显。 最后，内外销实力的不断增强，国内外市场持续开拓，将为 后续公司业绩向好打下坚实基础。 2、高管您好，能否请您介绍一下本期行业整体和行业内其 他主要企业的业绩表现？ 谢谢。 回复：尊敬的投资者，您好！2024 年度，随着落后产能的逐 步退出和全球需求稳定增长，公司主营的丁腈手套产品在手订单 充足，相关行业总体呈现回暖迹象。然而，美国不稳定的关税政 策，使得全球丁腈手套产品竞争格局发生较大变化，国内手套生 产商 ...

瘦吧科技创始人黄祥泓在会上发表重要致辞，结合行业痛点与企业近9年服务436万用户的实践成果，以 详实数据与前瞻性战略规划，展现出对行业发展趋势的深刻洞察与推动国民健康事业发展的坚定决心： 用科技重塑健康，让预防成为普惠每个人的生活方式。 (瘦吧科技创始人黄祥泓上台致辞) 响应国家战略，瘦吧科技顺势崛起 随着"健康中国2030"战略的深入推进，国民健康体重管理已成为慢性病防控的核心议题。面对超半数成 年人面临超重或肥胖的严峻现实，传统人工干预模式暴露出效率低、覆盖窄的短板，科技赋能迫在眉 睫。2016年，瘦吧科技应势而生，坚定不移践行"让更多人因我们而健康"的使命，依托AI与大数据的创 新应用，与国家战略同频共振，成为健康中国建设的先行者。 5月11日，由瘦吧科技主办、新华网（603888）联合发起，央广网、人民网特别支持的"健康体重·因AI 新生"国民健康体重管理计划发展大会暨"百亿健康补贴·一起来瘦吧"行动发布会在北京国际会议中心隆 重举行。大会聚焦AI技术与大健康产业的深度融合，发布多项重量级战略举措，旨在以科技之力推动 全民健康体重管理科学化、普惠化发展。 5·11行动发布，科技普惠与公益升级 在5月1 ...

证券代码： 301089 证券简称：拓新药业 拓新药业集团股份有限公司 投资者关系活动记录表 编号：20250514 投资者关系活动 类别 □特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 投资者网上提问 时间 2025 年 5 月 14 日 (周三) 下午 15:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 员姓名 1、董事、总经理杨邵华 2、董事会秘书杨钰华 3、财务总监焦慧娟 4、独立董事刘建伟 5、保荐代表人郑俊杰 投资者关系活动 主要内容介绍 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、截止上周最新的股东户数是多少？ 截至 2025 年 5 月 9 日，公司股东户数 16,802 户，感谢您的 关注！ 2、公司在海南注册公司是否是要考虑拓展海外市场 公司在海南设立全资子公司，利用地理位置与政策优势，为 拓展海外市场提供了良好的政策环境和 ...

Core Viewpoint - The article highlights the transformation of Dong'a County into a leading health and wellness hub, leveraging its rich heritage in traditional Chinese medicine, particularly the production of Ejiao, to create a comprehensive health industry ecosystem [1][7]. Group 1: Brand Development and Recognition - Dong'a County's "Kangyang Dong'a" brand was awarded the title of "Most Influential Brand in Shandong," showcasing its commitment to health and wellness [1]. - The county has established a cultural and industrial integration model, promoting the Ejiao industry as a key economic pillar [2][3]. Group 2: Cultural and Historical Significance - Ejiao, known as a "national treasure" and "blood-nourishing holy medicine," has a history of over 3,000 years, deeply rooted in the local culture and economy [1][2]. - The county has organized extensive research on Ejiao, compiling over 3,200 ancient recipes and traditional practices, which have been recognized in cultural research awards [2]. Group 3: Innovation and Modernization - Dong'a County is innovating within the Ejiao industry by integrating culture, tourism, and health, transitioning from traditional manufacturing to a multi-faceted industry model [2][4]. - The establishment of various cultural experience platforms and the creation of a national-level Ejiao museum reflect the county's efforts to modernize and promote its traditional practices [3][4]. Group 4: Economic Growth and Future Plans - In 2024, the county's health industry is projected to see significant growth, with industrial output, revenue, and profits expected to increase by 18%, 19%, and 27% respectively [7]. - Dong'a County aims to enhance its competitive advantages and develop a diverse health industry ecosystem, contributing to the "Healthy China" initiative [7].

5月13日，第36届医药经济信息发布会在广州召开。国家药监局副局长徐景和表示，要全面贯彻落实党 的二十届三中全会精神，落实《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量 发展的意见》，全过程深化药品监管改革、全方位筑牢药品安全底线、全链条支持产业高质量发展，为 保护和促进公众健康作出更大贡献。 药械审批 泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理 政策动向 国家药监局：全过程深化药品监管改革全方位筑牢药品安全底线 荣昌生物RC278获得临床试验申请受理通知书 5月12日，荣昌生物公告，注射用RC278的临床试验申请获CDE受理。RC278是公司自主研发的具有 First-in-Class/Best-in-Class潜质的ADC分子，能特异识别一个新型肿瘤靶点，在临床前研究中展现出广 5月13日，泽璟制药公告称，公司收到国家药品监督管理局核准签发的《受理通知书》，公司递交的盐 酸吉卡昔替尼片治疗重度斑秃的新药上市申请（NDA）获得受理。这是盐酸吉卡昔替尼片第二个申请 新药上市的适应症。盐酸吉卡昔替尼是一种新型的JAK抑制剂，对JAK激酶的四个亚型JAK1、JAK2、 JAK3 ...

昨天（5月12日），《苏州工业园区加快生物医药及大健康产业腾飞行动计划（2025-2027）》正式 发布。聚焦创新药、高端医疗器械、大健康等重点领域，《行动计划》重点围绕企业规模化发展、优质 增量项目落地、创新产品上市、创新产品应用推广、股权融资、信贷支持、人工智能赋能、体制机制创 新等八个方面，将通过择优精准扶持、构建"5511"企业培育体系，助力园区生物医药及大健康产业腾飞 发展。 以制度创新破解生物医药产业发展瓶颈，园区将按照《行动计划》，发挥中新合作和自贸区优势， 深入开展生物医药全产业链开放创新；纳入国家创新药临床试验审评审批试点和药品补充申请审评审批 试点，缩短审评审批时限；支持全球领先的食品、保健品在保证产品质量且符合法律法规及相应食品生 产许可审查细则等规定的情况下在苏州工业园综合保税区内从事分包装业务，分包装后的产品通过跨境 电商模式进入国内市场。 在支持企业规模化发展方面，园区将聚焦培优育强，重点支持企业加大固定资产投入、扩大企业规 模、做大营业收入、增大研发投入和上下游企业收并购；在加快优质增量项目落地投产方面，将聚焦招 大引强，重点支持世界500强、中国500强、中国医药工业百强企业， ...

每经记者｜孔泽思 每经编辑｜陈梦妤 ｜2025年5月12日 星期一｜ NO.1 深圳获批建设国家级知识产权快速维权中心 "深圳发布"微信公众号5月10日消息，近日，深圳市获国家知识产权局批复同意在福田区建设国家级知识产权快速维权中心。该中心将成为深圳市首家获批 的国家级知识产权快速维权机构，重点面向时尚设计产业提供知识产权快速维权服务。 点评：深圳将更好统筹知识产权创造、运用、保护、管理、服务全链条，以高效能的知识产权保护服务创新驱动发展。 NO.2 我国首艘深水铺管起重船出海作业 "珠海发布"微信公众号5月11日消息，我国首艘深水铺管起重船"海洋石油201"从广东珠海高栏国际码头启航，驶向中东区域海管作业现场，这是该船首次进 入国际市场作业。 点评："海洋石油201"出海作业对提升我国大型海洋工程船舶国际化运营能力具有重要意义。 NO.3 德国途易酒店集团中国首店落地深圳大鹏新区 5月9日，欧洲最大旅游集团德国途易酒店集团中国区首店——途易晟深圳曼湾度假酒店正式揭牌，其与大鹏新区签订的《旅游发展战略合作框架协议》同步 落地，双方在以"酒店集群开发+全产业链联动"模式开展深度合作方面达成重要共识。 点评：途易 ...

Core Viewpoint - Shengyuan Environmental Protection (300867) is strategically transforming into the health industry, focusing on taurine and its derivatives, which are expected to drive significant revenue growth for the company [1][2]. Group 1: Company Strategy and Developments - Shengyuan Environmental Protection held its 2024 annual shareholder meeting on May 9, approving 11 resolutions, including the 2024 Board of Directors' work report [1]. - The company has established a dual business model by expanding into the taurine market while consolidating its core waste management operations [1]. - The company is investing in a 40,000-ton annual production line for taurine in the Quangang Petrochemical Park, which is expected to commence production by the end of 2024 [2]. Group 2: Market Potential and Demand - The global taurine market is primarily dominated by China, which accounts for nearly 90% of the production capacity, while the U.S. relies heavily on imports due to a lack of domestic production [1][2]. - The demand for taurine is increasing in functional food and beverage sectors, particularly in energy drinks, as well as in pet food and feed additives [2]. - The aging population and rising chronic disease rates are further driving the demand for taurine in the pharmaceutical sector [2]. Group 3: Research and Policy Support - Recent scientific breakthroughs in taurine applications, including anti-aging and anti-cancer effects, have been reported in top-tier journals, indicating its growing market potential [1]. - The Chinese government has been increasingly supportive of the taurine industry, implementing policies to encourage the development of natural food additives and nutritional fortifiers [3]. - Shengyuan Environmental Protection is developing a comprehensive product matrix centered around taurine, including functional foods and health products, supported by a dedicated research institute [3].

新华信用杭州5月11日电（徐淑明）作为2025世界品牌莫干山大会的重要组成部分，以"促消费 树品牌 兴产业 惠民生"为主题的2025区域公用品牌信用建设论坛10日在德清举办。论坛上，2025大健康品牌典 型案例正式发布，50家机关企事业单位申报的相关案例入选。 （按申报单位名称首字母顺序排列） | 单位名称 | 案例名称 | | --- | --- | | 北京本草方源（亳州）药业科技有限公司 | 绿色农业与中药材产业融合发展实践 | | 滨州市民营经济发展服务中心 | 以"红心引领·暖阳服务"建设"心安民营"品质滨州 | | 长寿花食品股份有限公司 | 山东长寿花"花开长寿"的"五色图谱" | | 大城县红日古典家具有限公司 | 木养身心 健康家居 生态红木 健康生活 | | 福建省天材集团实业有限公司 | 古法制香焕新生 匠心品质护健康 | | 福州爱尚贝臣口腔门诊部有限公司 | 数智驱动，品质护航——贝臣齿科构建全周期口腔健 | | | 康管理新生态 | | 广西旅发健康疗养有限公司 | 广西旅发健康疗养：以国企品质打造医养游融合型旅 | | | 居康养和疗休养新模式 | | 海尔集团（青岛）金盈控股有 ...

Core Viewpoint - The recent advertisement featuring Kelong Pharmaceutical's chairman, Liu Gexin, showcasing his physique at the age of 75 has sparked discussions, with mixed opinions from the public regarding its authenticity and effectiveness compared to celebrity endorsements [1][4]. Summary by Sections Advertisement and Product Promotion - Liu Gexin, the chairman of Kelong Pharmaceutical, promotes the company's ergothioneine capsules, emphasizing their potential anti-aging benefits and claiming that the product's effectiveness in eliminating free radicals is 10-30 times greater than traditional ingredients like Vitamin C and Coenzyme Q10 [5]. - The capsules are priced at 1499 yuan for a bottle containing 60 capsules, and the advertisement has passed regulatory review, set to be broadcast soon [5]. Product Background and Market Potential - Ergothioneine is a rare amino acid with antioxidant, cell protection, and anti-inflammatory properties, showing promise in disease prevention and treatment, including neuroprotection and potential benefits for sleep and memory enhancement [8]. - The product is relatively uncommon in oral form, with more prevalence in skincare products [8]. Financial Performance - Kelong Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.39 billion yuan, and a 43.07% drop in net profit to 584 million yuan [10]. - The company's core infusion business continues to face challenges due to centralized procurement policies, leading to a significant revenue decline in its synthetic biology segment [10]. Strategic Direction - In light of declining financial performance, Kelong Pharmaceutical is venturing into the health and wellness sector, with Liu Gexin personally endorsing the high-end health products as a strategy to create a new growth avenue [12]. - Kelong Yongnian, a subsidiary focused on health products, was established in 2024 and is fully controlled by Kelong Pharmaceutical [12]. Leadership and Market Position - Liu Gexin, known as the "King of Infusion," has significant influence in the industry, with Kelong Pharmaceutical holding a leading market share of 22.1% in the infusion market as of 2008 [15]. - The chairman's family controls three publicly listed companies, with a combined market value exceeding 549 billion yuan [13]. Industry Trends - The trend of entrepreneurs endorsing their own products is becoming more common, with examples including Vanke's Wang Shi and Gree's Dong Mingzhu, indicating a shift towards personal branding in marketing strategies [16].